Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 605-610

  Mizutani, Yoichi ^a   Wada, Hiromi ^b   Yoshida, Osamu ^b   Fukushima, Masakazu ^c   Nakanishi, Hiroyuki ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Department of Thoracic Surgery ^*  (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Carcinoma, renal cell; Fluorouracil; Kidney; Orotate phosphoribosyltransferase; Tumor markers, biological

Indexed keywords

FLOXURIDINE PHOSPHATE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SYNTHESIS; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; PROGNOSIS; RNA SYNTHESIS;

EID: 0347759890     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000107833.03488.d2     Document Type: Article

References (20)

1. Bukowski, R. M.: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 80: 1198, 1997
2. Longley, D. B., Harkin, D. P. and Johnston, P. G.: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3: 330, 2003
3. Shirasaka, T., Shimamoto, Y. and Fukushima, M.: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res, 53: 4004, 1993
4. Kanai, F., Kawakami, T., Hamada, H., Sadata, A., Yoshida, Y., Tanaka, T. et al: Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res, 58: 1946, 1998
5. Mizutani, Y., Wada, H., Ogawa, O., Yoshida, O., Fukushima, M., Nonomura, N. et al: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer, 92: 510, 2001
6. Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Nonomura, M., Nakao, M. et al: Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res, 9: 1453, 2003
7. Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Kamoi, K. and Miki, T.: Prognostic significance of thymidine kinase activity in bladder carcinoma. Cancer, 95: 2120, 2002
8. Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Nakao, M. and Miki, T.: Significance of thymidine kinase activity in renal cell carcinoma. J Urol, 169: 706, 2003
9. Wu, X. X., Mizutani, Y., Kakehi, Y., Yoshida, O. and Ogawa, O.: Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res, 60: 2912, 2000
10. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida, O.: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res, 55: 590, 1995
11. Mizutani, Y., Nakanishi, H., Yoshida, O., Fukushima, M., Bonavida, B. and Miki, T.: Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer, 38: 167, 2002
12. Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Nakanishi, H., Nakao, M. et al: Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer, 39: 541, 2003
13. Danenberg, P. V.: Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochem Biophys Acta, 473: 73, 1977
14. Navalgund, L. G., Rossana, C., Muench, A. J. and Johnson, L. F.: Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem, 255: 7386, 1980
15. O'Neil, K. L., Grigsby, R. V. and Fairbairn, D. W.: Thymidine kinase: the future in breast cancer prognosis. Breast, 4: 79, 1995
16. Foekens, J. A., Romain, S., Look, M. P., Martin, P. M. and Klijn, J. G.: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res, 61: 1421, 2001
17. Ikenaka, K., Fukushima, M., Nakamura, H., Okamoto, M., Shirasaka, T. and Fujii, S.: Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Gann, 72: 590, 1981
18. Diasio, R. B., and Lu, Z.: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol, 12: 2239, 1994
19. Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J. and Diasio, R. B.: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res, 47: 2203, 1987
20. Mizutani, Y., Wada, H., Fukushima, M., Yoshida, O., Ukimura, O., Kawauchi, A. et al: The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer, 37: 569, 2001